

## Press Release

04 September 2024 08:45:00 CEST

# NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBKL)

The shareholders of 2cureX AB (publ) ("2cureX"), org. no. 559128-0077, are hereby invited to an extraordinary general meeting. The extraordinary general meeting will be held at 10:00 (CEST) on Tuesday 24 September 2024 at Malmö Live Hotel, located at Dag Hammarskjölds torg 4, 211 18 Malmö, Sweden.

### Notification of participation etc.

Shareholders who wish to attend the extraordinary general meeting must:

- be recorded as shareholders in the share register maintained by Euroclear Sweden AB on Monday 16st of September 2024, and;
- no later than Thursday 19st of September 2024 have given written notice of their participation by mail to 2cureX AB, c/o Talenom Consulting AB, Lilla Strandgatan, 261 22 Landskrona. Notice can also be provided by email to [ir@2curex.com](mailto:ir@2curex.com). The notification should state name, personal identification number or registration number, address, daytime phone number and when applicable information regarding any representative, proxy and or up to two assistants. If applicable, the notification must include authorization documents such as a certificate of registration or equivalent documents.

### Nominee-registered shares

A shareholder who has its shares registered with a nominee must, to be entitled to participate in the extraordinary general meeting, have the shares registered in its own name through the nominee, so that the shareholder is registered in the share register kept by Euroclear Sweden AB on the record date of Monday 16st of September 2024. Such registration may be temporary, known as voting rights registration. Shareholders who wish to register the shares in their own name must, in accordance with the respective nominee's routines, request that the nominee make such voting rights registration. Registration of voting rights that have been requested by shareholders at such a time that the registration has been made by the relevant nominee no later than Thursday 19st of September 2024 will be taken into account in the production of the share register.

### Proxy

Shareholders represented by proxy shall issue a written and dated power of attorney signed by the shareholder. A power of attorney issued by a legal entity shall have a registration certificate attached, or if such certificate does not exist, equivalent documents. The original power of attorney and any registration certificate should, in advance of the extraordinary general meeting, be sent to the company at the address above.

## Proposed agenda

1. Appointment of a Chairman of the extraordinary general meeting
2. Preparation and approval of the voting register
3. Approval of the agenda
4. Appointment of one (1) or two (2) persons to verify the minutes of the meeting
5. Determination of whether the extraordinary general meeting was duly convened
6. Appointment of Board of Directors
7. Closure of the extraordinary general meeting

### Appointment of Board of directors (item 6)

The Board of Directors propose that the extraordinary general meeting to elect Dan Honeywell and Nathaniel Hutley as new members of the Board of Directors.

The Board of Directors hereafter consists of Tonny Bülow-Nielsen, Ole Thastrup, Grith Hagel, Dan Honeywell and Nathaniel Hutley.

This proposal stems from a significant restructuring of 2cureX, where the company has been split into two independent entities: 2cureX AB and 2cureX A/S. 2cureX AB will as publicly listed company focus on a robust commercial strategy to become a leader in Functional Precision Oncology by developing direct-to-patient offerings. 2cureX A/S, operating privately, will drive product development. The two companies will collaborate closely, combining commercial and innovative development efforts.

The expansion of the Board will provide substantial strengthening of the commercial competences being essential for executing the new business plan for 2cureX AB.

**Dan Honeywell** is an accomplished Tech Founder and Business Leader, with over 15 years of expertise in building, scaling, and advising high-growth companies. He is recognised for pioneering innovations in the UK healthcare sector and deep expertise in category design, with a proven track record in driving substantial business transformations and leveraging AI for global market expansion.

Dan was Founder and CEO of Zedsen, a pioneering UK MedTech company that changed the face of the UK healthcare innovation sector. He exhibited extraordinary leadership and financial understanding, and the company's valuation soared from a modest inception to an impressive £100+ million in five years. The company was one of the Top 10 fastest-growing companies in the UK.

Dan is an active member of the Young President's Organisation (YPO). He is Membership Director for the Greater London Chapter and sits on the boards of the Healthcare Business Network and Health and Wellness Network.

**Nat Hutley** is the visionary founder and CEO of Koodos, a London-based strategic advisory and venture capital firm dedicated to empowering businesses committed to positive impact. With a career that spans multiple industries and regions, Nat brings a wealth of experience, entrepreneurial spirit, and a deep understanding of global markets to 2cureX.

Nat's professional journey began in shipbroking in Australia, followed by a successful transition into commodity trading in the UK. Driven by a passion for growth and new challenges, he spent a decade in Southeast Asia, where he played a pivotal role in pioneering and scaling businesses across the hospitality, recruitment, oil and gas, and renewable energy sectors in Myanmar. Since returning to the UK, Nat has channelled his expertise into founding Koodos, where he oversees operations, strategic advisory, business development, and investments.

His track record of building and scaling businesses, combined with his dedication to impactful ventures, makes him a valuable addition to the 2cureX team as they continue to advance their mission and deliver exceptional outcomes.

Dan and Nat's appointments to the board of 2cureX represents an exciting opportunity to bring their visionary leadership and strategic insight to a company at the forefront of innovation in the commercialization of Functional Precision Oncology through a novel Direct-to-patient strategy.

#### Other

The notice and proxy forms will be made available at the premises of the company, 2cureX, Fruebjergvej 3, 2100 Copenhagen, Denmark and on the company's website ([www.2curex.com](http://www.2curex.com)) and will be sent to the shareholders who request it and state their postal address.

Shareholders are informed of their right under Chapter 7, Section 32 of the Swedish Companies Act to request information from the Board of directors and the CEO.

---

Malmö in September 2024

2cureX AB (publ)

The Board of directors

For more information about 2cureX:

---

Ole Thastrup, CEO

E-mail: [ot@2curex.com](mailto:ot@2curex.com)

Telephone: +45 2211 5399

[www.2curex.com](http://www.2curex.com)

Kenneth Graabek Johansen, Chief Financial Officer

E-mail: [kgj@2curex.com](mailto:kgj@2curex.com)

Telephone: +45 23 49 02 27

[www.2curex.com](http://www.2curex.com)

## About 2cureX

---

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit [www.2cureX.com](http://www.2cureX.com)

Certified Adviser: Redeye AB

## Attachments

---

[NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB \(PUBKL\)](#)